Skip to main content

Table 3 Antiplatelet/anticoagulation management

From: In-office laryngeal procedures (IOLP) in Canada: current safety practices and procedural care

  Would Continue N = 15 (%) Would StopaN = 15 (%) Would perform IOLP if patient cannot stop
ASA 81 mg 11 (73.3) 4 (26.7) 15 (100.0)
NSAIDs 12 (80.0) 3 (20.0) 13 (86.7)
Clopidogrel 5 (33.2) 10 (66.7) 7 (46.7)
New agents (i.e. dabigatran) 8 (53.5) 7 (46.7) 5 (33.3)
Warfarin 3 (20.0)b 12 (80.0) c 4 (26.7)d
  1. a Stop from 3 to 7 days prior to procedure
  2. b 1 respondent specified if INR less than 3.5
  3. c With or without bridging
  4. d 1; only for injection laryngosplasty, 1; only if INR over 2.5 (hold or modify)